Back to top
more

OSMOTICA PHARM (OSMT)

(Delayed Data from NSDQ)

$3.98 USD

3.98
34,365

+0.05 (1.27%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.97 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Osmotica Pharmaceuticals (OSMT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Osmotica Pharmaceuticals (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OSMOTICA PHARM (OSMT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -66.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will OSMOTICA PHARM (OSMT) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OSMOTICA PHARM (OSMT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 34.78% and -25.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate OSMOTICA PHARM (OSMT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OSMOTICA PHARM (OSMT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

OSMOTICA PHARM (OSMT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Osmotica Pharmaceuticals (OSMT) in Focus: Stock Moves 6.7% Higher

by Zacks Equity Research

Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

OSMOTICA PHARM (OSMT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 58.33% and 11.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

OSMOTICA PHARM (OSMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OSMOTICA PHARM (OSMT) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 500.00% and 11.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

OSMT or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OSMT vs. ILMN: Which Stock Is the Better Value Option?

Is OSMOTICA PHARM (OSMT) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

OSMT vs. QGEN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

OSMT vs. QGEN: Which Stock Is the Better Value Option?

Moving Average Crossover Alert: Osmotica Pharmaceuticals

by Zacks Equity Research

Osmotica Pharmaceuticals is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Kinjel Shah headshot

Buy These 6 Best Value Stocks to Make the Most of P/B Ratio

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

Sweta Killa headshot

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

by Sweta Killa

Healthcare bounced back with an outperformance starting the fourth quarter.

Is OSMOTICA PHARM (OSMT) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

OSMT or QGEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OSMT vs. QGEN: Which Stock Is the Better Value Option?